Rebecca Roth

List of Publications by Year
in descending order

60 papers	7,280 citations	117571 34 h-index	118793 62 g-index
63 all docs	63 docs citations	63 times ranked	11139 citing authors

#	Article	IF	Citations
1	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	9.4	960
2	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncology, The, 2012, 13, 385-394.	5.1	753
3	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	3.0	596
4	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
5	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics, 2009, 41, 585-590.	9.4	434
6	Genome-wide association studies identify four ER negative–specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	9.4	374
7	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	9.4	321
8	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer. Nature Genetics, 2011, 43, 1210-1214.	9.4	279
9	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	9.4	256
10	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	9.4	235
11	K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. Journal of Thoracic Oncology, 2019, 14, 606-616.	0.5	178
12	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer, 2013, 20, 251-262.	1.6	169
13	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular Genetics, 2012, 21, 5373-5384.	1.4	168
14	Gene–environment interactions for complex traits: definitions, methodological requirements and challenges. European Journal of Human Genetics, 2008, 16, 1164-1172.	1.4	161
15	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	1.4	152
16	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	5.8	144
17	Evidence of Gene–Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. PLoS Genetics, 2013, 9, e1003284.	1.5	136
18	Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. Cancer Research, 2011, 71, 6240-6249.	0.4	109

#	Article	IF	Citations
19	Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Research, 2011, 13, R74.	2.2	101
20	Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer Research, 2016, 76, 5103-5114.	0.4	100
21	Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Research, 2010, 12, R110.	2.2	82
22	A Genome-wide Association Study of Early-Onset Breast Cancer Identifies *PFKM* as a Novel Breast Cancer Gene and Supports a Common Genetic Spectrum for Breast Cancer at Any Age. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 658-669.	1.1	77
23	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium€. Human Molecular Genetics, 2011, 20, 4693-4706.	1.4	71
24	Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors. Cancer Epidemiology, 2011, 35, 345-352.	0.8	69
25	Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. Journal of Thoracic Oncology, 2016, 11, 122-127.	0.5	65
26	Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 880-890.	1.1	54
27	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	1.1	51
28	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	1.1	49
29	Prevalence of inflammatory bowel disease: estimates for 2010 and trends in Germany from a large insurance-based regional cohort. Scandinavian Journal of Gastroenterology, 2014, 49, 1325-1335.	0.6	49
30	Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptor€"Negative Breast Cancer Survival. Journal of the National Cancer Institute, 2010, 102, 650-662.	3.0	48
31	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750.	3.2	47
32	Use of an Enrichment Broth Improves Detection of Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae in Clinical Stool Samples. Journal of Clinical Microbiology, 2016, 54, 467-470.	1.8	45
33	Sample size requirements for indirect association studies of gene€"environment interactions (G × E). Genetic Epidemiology, 2008, 32, 235-245.	0.6	39
34	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	1.4	38
35	11q13 is a susceptibility locus for hormone receptor positive breast cancer. Human Mutation, 2012, 33, 1123-1132.	1.1	35
36	Polymorphisms in oxidative stress€related genes and postmenopausal breast cancer risk. International Journal of Cancer, 2011, 129, 1467-1476.	2.3	32

#	Article	IF	Citations
37	Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation. European Journal of Clinical Pharmacology, 2018, 74, 1317-1325.	0.8	28
38	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	1.1	27
39	Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome–wide interaction study. Endocrine-Related Cancer, 2013, 20, 875-887.	1.6	26
40	EffenDys–"Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. Journal of Pain and Symptom Management, 2016, 52, 617-625.	0.6	25
41	Polymorphism in the <i>GALNT1</i> Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women: The Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 600-604.	1.1	23
42	Modification of menopausal hormone therapy-associated colorectal cancer risk by polymorphisms in sex steroid signaling, metabolism and transport related genes. Endocrine-Related Cancer, 2011, 18, 371-384.	1.6	23
43	A multicenter paper-based and web-based system for collecting patient-reported outcome measures in patients undergoing local treatment for prostate cancer: first experiences. Journal of Patient-Reported Outcomes, 2020, 4, 56.	0.9	19
44	A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication. Breast Cancer Research and Treatment, 2013, 138, 529-542.	1.1	18
45	Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatment. World Journal of Urology, 2021, 39, 27-36.	1.2	12
46	A randomised controlled multicentre investigator-blinded clinical trial comparing efficacy and safety of surgery versus complex physical decongestive therapy for lipedema (LIPLEG). Trials, 2021, 22, 758.	0.7	12
47	Use of psycho–oncological services by prostate cancer patients: A multilevel analysis. Cancer Medicine, 2020, 9, 3680-3690.	1.3	11
48	The Frequency of Prescription of Immediate-Release Nifedipine for Elderly Patients in Germany. Deutsches A&#x0308;rzteblatt International, 2012, 109, 215-9.	0.6	10
49	Copy number variations of <i>GSTT1</i> and <i>GSTM1</i>, colorectal cancer risk and possible effect modification of cigarette smoking and menopausal hormone therapy. International Journal of Cancer, 2012, 131, E841-8.	2.3	10
50	Genome-Wide Association Study for Ovarian Cancer Susceptibility Using Pooled DNA. Twin Research and Human Genetics, 2012, 15, 615-623.	0.3	8
51	Variation across operating sites in urinary and sexual outcomes after radical prostatectomy in localized and locally advanced prostate cancer. World Journal of Urology, 2022, 40, 1437-1446.	1.2	7
52	Shared ancestral susceptibility to colorectal cancer and other nutrition related diseases. BMC Medical Genetics, 2012, 13, 94.	2.1	6
53	Protocol of the Cologne Corona Surveillance (CoCoS) Study– a prospective population-based cohort study. BMC Public Health, 2021, 21, 1295.	1.2	6
54	Comparison of the power of haplotype-based versus single- and multilocus association methods for gene Ã— environment (gene Ã— sex) interactions and application to gene Ã— smoking and gene Ã— sex interactions in rheumatoid arthritis. BMC Proceedings, 2007, 1, S73.	1.8	5

#	Article	IF	Citations
55	7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. Journal of Medical Genetics, 2011, 48, 698-702.	1.5	5
56	Impact of video quality when evaluating video-assisted cardiopulmonary resuscitation: a randomized, controlled simulation trial. BMC Emergency Medicine, 2021, 21, 96.	0.7	5
57	Comparison of Different Haplotype-Based Haplotype-Based Association Methods for Gene-Environment (GÃ—E) Interactions in Case-Control Studies when Haplotype-Phase Is Ambiguous. Human Heredity, 2009, 68, 252-267.	0.4	4
58	Video-assisted cardiopulmonary resuscitation: Does the camera perspective matter? A randomized, controlled simulation trial. Journal of Telemedicine and Telecare, 2021, , 1357633X2110284.	1.4	4
59	Representation of genetic association via attributable familial relative risks in order to identify polymorphisms functionally relevant to rheumatoid arthritis. BMC Proceedings, 2009, 3, S10.	1.8	2
60	Age-Linked Treatment Rates. Deutsches A&#x0308;rzteblatt International, 2016, 113, 287-8.	0.6	0